文献速递鼻科

度普利尤单抗治疗慢性鼻窦炎伴鼻息肉期间的嗅觉筛查

Screening olfaction under dupilumab in chronic rhinosinusitis with nasal polyps.
PubMed 文献 · Rhinology · 2024-01-01

本研究纳入26例接受度普利尤单抗(每两周皮下注射300mg/2ml)治疗的慢性鼻窦炎伴鼻息肉患者,在基线及第1、3、6个月评估嗅觉(SST-12)、FeNO和鼻息肉评分(NPS)。治疗后1个月FeNO、SNOT评分和NPS大幅下降,SST-12评分仅在3个月后显著改善;6个月时81%患者达到嗅觉正常,失嗅患病率降至9.5%。

要点

  • 度普利尤单抗治疗1个月后FeNO、SNOT评分和NPS大幅下降,SST-12评分3个月后才显著改善。
  • 6个月时81%患者达到嗅觉正常,失嗅患病率降至9.5%。
  • 基线和6个月时SST-12与NPS呈显著负相关,与FeNO或SNOT评分无显著相关,年龄与嗅觉不相关。

核心结论

  • 度普利尤单抗在恢复慢性鼻窦炎伴鼻息肉患者嗅觉方面显示有效,6个月治疗后有超过80%的患者达到嗅觉正常,凸显该药管理这一棘手症状的效果。

研究设计与样本

  • 纳入26例符合度普利尤单抗治疗条件的慢性鼻窦炎伴鼻息肉患者,接受每两周皮下注射Dupixent®(300mg/2ml度普利尤单抗)。
  • 在基线及第1、3、6个月评估12项Sniffin' Sticks测试(SST-12)、呼出气一氧化氮(FeNO)和鼻息肉评分(NPS),患者每周完成鼻腔鼻窦结局测试(SNOT-22)。

主要发现

  • 治疗1个月后,度普利尤单抗使FeNO、SNOT评分和NPS大幅下降,而SST-12评分仅在3个月后显著改善。
  • 6个月后81%的患者达到嗅觉正常,失嗅患病率降至9.5%。
  • 基线和6个月时,嗅觉(SST-12)与息肉严重程度(NPS)呈显著负相关;SST-12与FeNO或SNOT评分之间无显著相关性。
  • 年龄与嗅觉无相关性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently leads to olfactory dysfunction. This study aimed to assess the impact of dupilumab on CRSwNP patients, focusing on olfactory outcomes and potential correlations with other clinical factors. METHODS: CRSwNP patients eligible for dupilumab therapy received subcutaneous Dupixent® injections every two weeks (300mg/2ml dupilumab). The 12-item Sniffin' Sticks Test (SST-12), fractional exhaled nitric oxide (FeNO) and Nasal Polyp Score (NPS) were assessed at baseline and after one, three, and six months. Patients also completed the Sino-Nasal Outcome Test (SNOT-22) weekly. RESULTS: 26 CRSwNP patients were included. After one month, dupilumab led to substantial reductions in FeNO, SNOT scores, andNPS, whereas SST-12 scores improved significantly only after three months. A shift toward normosmia occurred, with 81% achieving normosmia after six months, and a drop in anosmia prevalence to 9.5%. Significant negative correlations between olfaction (SST-12) and polyp severity (NPS) at baseline and after six months were found, while no significant correlations were observed between SST-12 and FeNO or SNOT scores. Age did not correlate with olfaction. CONCLUSIONS: Dupilumab demonstrated efficacy in restoring olfaction in CRSwNP patients. Reaching normosmia in over 80% ofpatients after six months of treatment underscores the drug's effectiveness in managing this challenging symptom.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Mauthe T, Meerwein CM, Ryser FS, et al. Screening olfaction under dupilumab in chronic rhinosinusitis with nasal polyps. Rhinology. 2024. PMID: 38949841. doi:10.4193/Rhin23.476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。